Clinical trial · Observational
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
NCT07035067CI-TRIAL-00107477terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment
Summary
Brief summary (as posted)
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Caregiver Burden | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Patient Burden | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with PROC part of Ovarian Cancer Canada mailing lists
- interventionNames
- Other: No intervention
- label
- Caregiver of PROC patients part of Ovarian Cancer Canada mailing lists
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- To estimate the quality of life of patient with ovarian cancer
- timeFrame
- At recruitment
- description
- Using the the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and EuroQol 5-dimendion 5-level (EQ-5D-5L)
Secondary outcomes (4)
- measure
- Patient's symptoms assessment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patient Inclusion Criteria 1. ≥18 years old 2. Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin) 3. Ability to read and understand French or English 4. Signature of ICF Patients Exclusion Criteria 1. Patients with PSOC, defined as those who: 1. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or; 2. Are still on platinum chemotherapy or; 3. Receive maintenance therapy. 2. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose Caregivers Inclusion Criteria: 1. ≥18 years old 2. Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey. 3. Ability to read and understand French or English 4. Signature of ICF. Caregivers Exclusion Criteria: 1. Caregivers of patients with PSOC (see definition above) 2. Caregivers of PROC patients who have passed away 3. Caregivers of platinum-refractory patients (see definition above)
References
Publications (0)
Data not yet available
No reference posted for this study.